The nicotine market: An attempt to estimate the nicotine intake from various sources and the total nicotine consumption in some countries

Nicotine and Tobacco Research

Volumn 7, Issue 3, 2005, Pages 343-350

  Fagerström, Karl ^a  

^a Fagerstrom Consulting AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; NICOTINE GUM;

ARTICLE; AUSTRIA; CIGARETTE SMOKING; CONSUMER; DENMARK; FINLAND; HEALTH HAZARD; HUMAN; LOZENGE; MARKETING; NICOTINE REPLACEMENT THERAPY; NORWAY; PREVALENCE; PRIORITY JOURNAL; PUBLIC OPINION; SMOKELESS TOBACCO; SMOKING CESSATION; SWEDEN; TOBACCO; TRANSDERMAL PATCH; UNITED STATES;

ADOLESCENT; ADULT; DEVELOPED COUNTRIES; FEMALE; HUMANS; MALE; NICOTINE; TOBACCO USE DISORDER;

EID: 26444450566     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1080/14622200500124875     Document Type: Article

References (37)

1. Andersson, G., Axell, T., & Curvall, M. (1995). Reduction in nicotine intake and oral mucosal changes among Swedish oral moist snuff after switching to a low-nicotine product. Journal of Oral Pathology & Medicine, 24, 244-250.
2. Andersson, G., Björnberg, G., & Curvall, M. (1994). Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: A comparative study. Journal of Oral Pathology & Medicine, 23, 161-167.
3. Andersson, G., Kazemi Vala, E., & Curvall, M. (1997). The influence of cigarette consumption and smoking machine yields of tar and nicotine on the uptake and oral mucosal lesions in smokers. Journal of Oral Pathology & Medicine, 26, 117-123.
4. Asplund, K. (2003). Smokeless tobacco and cardiovascular disease. Progress in Cardiovascular Diseases, 45, 383-394.
5. Benowitz, N. L. (1995). Clinical pharmacology of nicotine patches. European Journal of Pharmaceutics and Biopharmaceutics, 41, 168-174.
6. Benowitz, N. L. (1999). Snuff, nicotine and cardiovascular disease: Implications for tobacco control. Journal of the American College of Cardiology, 34, 1791-1793.
7. Benowitz, N. L., Jacob, P., Fong, I., & Gupta, S. (1994). Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. Journal of Pharmacology and Experimental Therapeutics, 268, 296-303.
8. Benowitz, N. L., Porchet, H., Sheiner, L., & Jacob, P., III. (1988). Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. Clinical Pharmacology and Therapeutics, 44, 23-28.
9. Benowitz, N. L., Zevin, S., & Jacob, P., III. (1997). Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. British Journal of Clinical Pharmacology, 43, 259-267.
10. Bergström, M., Nordberg, A., & Lunell, E. (1995). Regional disposition of inhaled 11C-nicotine vapor in the human airway visualized by positron emission tomography. Clinical Pharmacology and Therapeutics, 57, 309-317.
11. Castagnoli, K. P., Steyn, S. J., Petzer, J. P., Van der Schyf, C. J., & Castagnoli, N. (2001). Neuroprotection in the MPTP Parkinsonian C57BL/6 mouse model by a compound isolated from tobacco. Chemical Research in Toxicology, 14, 523-527.
12. Crane, J., Blakely, T., & Hill, S. (2004). Time for major road-works on the tobacco road? The New Zealand Medical Journal, 1190, U801.
13. Fagerström, K. O., Boyle, P., Kunze, M., & Zatonski, W. (2001). The anti-smoking climate in EU countries and Poland. Lung Cancer, 32, 1-5.
14. Fant, R. V., Henningfield, J. E., & Nelson, R. A. (1999). Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tobacco Control, 8, 387-392.
15. Foulds, J., Ramström, L., burke, M., & Fagerström, K. (2003). Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tobacco Control, 12, 349-359.
16. Fowler, J. S., Logan, J., Wang, G. J., & Volkow, N. D. (2003). Monoamine oxidase and cigarette smoking. Neurotoxicology, 24, 75-82.
17. Gray, N., & Boyle, P. (2003). The future of the nicotine addiction market. The Lancet, 362, 845-846.
18. Holm, H., Jarvis, M. J., & Russell, M. A. H. (1992). Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology, 108, 507-511.
19. Houtsmuller, E. J., Henningfield, J. E., & Stitzer, M. (2003). Subjective effects of the nicotine lozenge: Assessment of abuse liability. Psychopharmacology, 167, 20-27.
20. Jarvis, M. J., Boreham, R., Primatesta, P., Feyerabend, C., & Bryant, A. (2001). Nicotine yield from machine-smoked cigarettes and nicotine intake in smokers: Evidence from a representative population survey. Journal of the National Cancer Institute, 93, 134-138.
21. Kozlowski, L. T., Metha, N. Y., Sweeney, C. T., Schwartz, S. S., Vogler, G. P., Jarvis, M. J., & West, R. J. (1998). Filter ventilation and nicotine content of cigarettes from Canada, the United Kingdom, and the United States. Tobacco Control, 7, 369-375.
22. Kozlowski, L. T., Strasser, A. A., Giovino, G., Erickson, P. A., & Terza, J. V. (200 1). Applying the risk/use equilibrium: Use medicinal nicotine now for harm reduction. Tobacco Control, 10, 201-203.
23. Kunin, D., Latendresse, M. W., Gaskin, S., Smith, B. R., & Amit, Z. (2000). Pre-exposure effects of nicotine and acetaldehyde on conditioned taste aversion induced by both drugs. Pharmacology, Biochemistry, and Behavior, 66, 695-699.
24. Lunell, E., & Lunell, M. (2005). Steady-state nicotine plasma levels following use of four different types of Swedish snus compared with 2-mg Nicorette chewing gum: a crossover study. Nicotine & Tobacco Research, 7, 397-403.
25. Molander, L., Lunell, E., Andersson, B., & Kuylenstierna, F. (1996). Dose related and absolute bioavailability of nicotine from a nicotine vapor inhaler. Clinical Pharmacology and Therapeutics, 59, 394-400.
26. Nemeth-Coslett, R., Henningfield, J. E., O'Keeffe, M. K., & Griffiths, R. R. (1987). Nicotine gum: Dose related effects on cigarette smoking and subjective ratings. Psychopharmacology, 92, 424-430.
27. Peto, R., Lopez, A. D., Boreham, J., & Tuhn, M. (1996). Mortality from smoking worldwide. British Medical Bulletin, 52, 12-21.
28. Ramström, L. (2002, October). Patterns of use: A gate leading to smoking, or a way o give up? Paper presented at the fourth annual meeting of the Society for Research on Nicotine and Tobacco-Europe, Santander, Spain.
29. Shafey, O., Dolwick, S., & Guindon, G. E. (2003) Tobacco control country profiles (2nd ed.). Atlanta, GA: American Cancer Society.
30. Statistics Austria. (2003). Austrian tobacco statistics, Table 23.12. Retrieved November 30, 2004, from www.statistik.at/cgi-bin/jahr-buch.pl?kapitel=23&sprache=d
31. Svenson, C. K. (1987). Clinical pharmacokinetics of nicotine. Clinical Pharmacokinetics, 12, 30-40.
32. Tomar, S. L., Connolly, G., Wilkenfeld, J., & Henningfield, J. (2003). Declining smoking in Sweden: Is Swedish Match getting the credit for Swedish tobacco control's efforts? Tobacco Control, 12, 368-371.
33. Ueda, K., Kawachi, I., Nakamura, M., Nogami, H., Shirokawa, N., Masui, S., Okayama, A., & Oshima, A. (2002). Cigarette nicotine yields and nicotine intake among Japanese male workers. Tobacco Control, 11, 55-60.
34. U.S. Department of Agriculture Economic Research Service. (2002). U.S. tobacco statistics. Retrieved November 30, 2004, from http://mannlib.cornell.edu/reports/erssor/speciahty/tbs-bb/2003/ tbs2003.pdf
35. VECA HB. (2003). Nordic tobacco statistics. Retrieved from www.statveca.com
36. Warner, K. E., Slade, J., & Sweanor, D. (1997). The emerging market for long term nicotine maintenance. The Journal of the American Medical Association, 278, 1087-1092.
37. The World Bank. (1999). Curbing the epidemic. Washington, DC: Author.